Fructose and Lactose Intolerance and Malabsorption in Functional Gastrointestinal Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02085889|
Recruitment Status : Recruiting
First Posted : March 13, 2014
Last Update Posted : March 30, 2021
Background: The association of fructose and lactose intolerance and malabsorption with the symptoms of different functional gastrointestinal disorders (FGID) is unclear. The mechanisms behind the multi-organ symptoms remain unclear. Both FGID and saccharide intolerances are common (>10% of any given population). Dietary modification based on intolerance diagnostics could provide an effective treatment for FGID, which are otherwise difficult to treat.
Aim: To investigate the prevalence and interrelationships of fructose and lactose intolerance (symptom induction) and malabsorption (breath test gas production) and their association with clinical GI as well as non-GI symptoms in FGID and the outcome of standard dietary intervention. Mechanisms related to symptom genesis will be investigated using metabolomic analysis of plasma and urine by gas chromatography/time-of-flight mass spectrometry (GC/TOFMS).
Methods: Fructose and lactose intolerance (defined by positive symptom index) and malabsorption (defined by increased hydrogen/methane) will be determined in successive male and female FGID patients in a single center using breath-testing. Symptoms will be recorded using standardised questionnaires and the Rome III criteria. The prevalence of the intolerances in the different FGID subgroups and the associations between breath testing results, clinical symptoms and the outcome of dietary modification will be assessed. Factors predictive of the outcome of dietary modulation will be screened for. GC/TOFMS will be used to assess the human and microbial metabolome in urine and plasma.
|Condition or disease||Intervention/treatment|
|Functional Gastrointestinal Disorders Lactose Intolerance Fructose Intolerance||Other: no intervention: observational study|
|Study Type :||Observational|
|Estimated Enrollment :||3000 participants|
|Official Title:||Fructose and Lactose Intolerance and Malabsorption: the Relationship Between Metabolism and Symptoms in Functional Gastrointestinal Disorders|
|Actual Study Start Date :||March 1, 2019|
|Estimated Primary Completion Date :||March 2022|
|Estimated Study Completion Date :||December 2022|
lactose intolerance fructose intolerance neither intolerance
Other: no intervention: observational study
- Number with adequate symptom relief [ Time Frame: 6-12 weeks ]adequate symptom relief in response to reduction of fermentable sugars
- Association between adequate symptom relief and test variables [ Time Frame: 6-12 weeks ]association between demographic, breath test and metabolomic factors and adequate relief due to dietary modification
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02085889
|Contact: Clive Wilder-Smith, MDfirstname.lastname@example.org|
|Gastoenterology Group Practice||Recruiting|
|Contact: Clive Wilder-Smith, MD +41313123737 email@example.com|
|Principal Investigator: Clive Wilder-Smith, MD|
|Principal Investigator:||Clive Wilder-Smith, MD||Brain-Gut Research Group|